B1 Cont'd

2. (amended) A vaccine product, which is [DNA or RNA or a derivative thereof, which upon appropriate administration to humans or animals will lead to the production of] a Recognin or a derivative thereof which contains the immunological specificity of malignin, Recognin L or Recognin M, which upon administration to humans or animals, [in turn] will cause [to be inhibited or destroyed] cancer cells, regardless of cell type, to be inhibited or destroyed and will prevent the development of clinical cancer, or if it has already developed, [treat clinical cancer] will destroy the cancer cells or inhibit their growth.

A2

REMARKS

A brief description of the Drawings has been added to the specification in response to the Examiner's suggestion.

A reference to US patent No. 4,976,957 has been added.

Claims 1 and 2 have been elected for prosecution in the present application in response to the Examiner's restriction requirement. Claims 1 and 2 have been amended to particularly point out and distinctly claim the subject matter of the invention.

With regard to the Examiner's statement that the objection under 35 U.S.C. § 112, first paragraph , "as failing to teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure", the Applicant wishes to draw the Examiner's attention to:

1) Example 2, page 11, lines 6 to 23, in which is taught how to make malignin, and also one derivative of malignin which contains the immunological specificity of malignin, TARGET reagent.